Clinical Trial Update: To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SP-002 in combination with vismodegib for locally advanced basal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• SP-002
• Vismodegib (Vismodegib)

Snippet

Sponsor: Stamford Pharmaceuticals, Inc. | Conditions: Basal Cell Carcinoma | Phase 2 | Status: RECRUITING